SCHEMBL14157151

SCHEMBL14157151

Oc1ccc(-c2nc(Br)cs2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
KDM4E B2RXH2 5/20 0.53
LMNA P02545 5/20 0.53
GAA P10253 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 4/20 0.53
POLB P06746 3/20 0.53
HPGD P15428 3/20 0.53
ALOX12 P18054 3/20 0.53
CDK5 Q00535 2/20 0.53
CDK5R1 Q15078 2/20 0.53
MEN1 O00255 2/20 0.53
PKM P14618 2/20 0.53
KMT2A Q03164 2/20 0.53
ESR2 Q92731 2/20 0.53
USP2 O75604 2/20 0.53
ALOX15 P16050 2/20 0.53
TSHR P16473 2/20 0.53
HSD17B10 Q99714 2/20 0.53
HSP90AA1 P07900 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67333 0.80 KDM4E (0.56) MAPTKDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL18171968 0.80 GFER (0.58) MAPTKDM4ELMNAGAASMN1; SMN2
SCHEMBL20875121 0.79 KDM4E (0.59) MAPTKDM4ELMNASMN1; SMN2POLB
SCHEMBL21914370 0.79 MAPT (0.56) MAPTKDM4ELMNAGAASMN1; SMN2
SCHEMBL1954255 0.79 KDM4E (0.53) MAPTKDM4ELMNAGAASMN1; SMN2
SCHEMBL26123239 0.78 KDM4E (0.73) MAPTKDM4ELMNAGAASMN1; SMN2
SCHEMBL26118261 0.78 KDM4E (0.73) MAPTKDM4ELMNAGAASMN1; SMN2
SCHEMBL1181195 0.78 KDM4E (0.75) MAPTKDM4ELMNAGAASMN1; SMN2
SCHEMBL3182382 0.76 KDM4E (0.54) MAPTKDM4ELMNAGAASMN1; SMN2
SCHEMBL2155406 0.76 CYP19A1 (0.40) KDM4ELMNASMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 US disclosed
EP-3626699-B1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2023-07-12 EP disclosed
EP-3626699-A1 SSAO INHIBITOR Shandong Danhong Pharmaceutical Co., Ltd. (CN) 2020-03-25 EP disclosed
WO-2012170371-A1 COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS N30 PHARMACEUTICALS, LLC (US) 2012-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 MAPT 2119/4885KDM4E 3601/4885LMNA 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.